Trial Profile
Postoperative Replacement of Intraoperative Iron Losses
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms POREIIL
- Sponsors CSL Vifor
- 30 Mar 2022 Planned End Date changed from 31 Oct 2022 to 1 Dec 2023.
- 30 Mar 2022 Planned primary completion date changed from 31 Oct 2022 to 31 Oct 2023.
- 28 Feb 2020 Status changed from not yet recruiting to recruiting.